Evidence map›Paper›PMID 35291260›Full record

ReviewThe Journal of clinical and aesthetic dermatology2021

New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications.

Risha Bellomo, Matthew Brunner, Ella Tadjally

Abstract readReview
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Acne among Patients Visiting Outpatient Department of Dermatology Centres.JNMA; journal of the Nepal Medical Association · 2023
    Article
  7. Oral Isotretinoin and Its Uses in Dermatology: A Review.Drug design, development and therapy · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Risha BellomoDr. Bellomo is with Allele Medical, in Orlando, Florida. Dr Brunner is with the Dermatology & Skin Surgery Center P.C., in Stockbridge, Georgia.
Matthew BrunnerDr. Bellomo is with Allele Medical, in Orlando, Florida. Dr Brunner is with the Dermatology & Skin Surgery Center P.C., in Stockbridge, Georgia.
Ella TadjallyDr. Bellomo is with Allele Medical, in Orlando, Florida. Dr Brunner is with the Dermatology & Skin Surgery Center P.C., in Stockbridge, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Isotretinoin is a widely used and effective drug in the treatment of severe, recalcitrant, nodular acne. However, its poor aqueous solubility limits oral bioavailability and requires administration with a high-fat, high-calorie meal (HF/HC) for optimal absorption; poor patient adherence may decrease effective dosing and treatment efficacy. Objective: This review covers the properties of the lidose isotretinoin and micronized isotretinoin formulations and their use in acne therapy. Method of Literature Search: PubMed was searched using the terms Results: Our review discusses pathology and approved treatment options for acne; provides mechanism of action of isotretinoin; presents clinical challenges associated with isotretinoin safety; and summarizes implications in clinical practice. Newer formulations show enhanced bioavailability in both fed and fasting states. Limitations: Few published studies of real-world use of the identified formulations were available. Conclusion: Newer drug delivery technologies can simplify isotretinoin use while maximizing bioavailability and efficacy. Based on our analysis, lidose isotretinoin and micronized isotretinoin improve oral bioavailability, pharmacological bioactivity, and increase therapeutic efficacy in patients who are unwilling or unable to consistently take the medication with an HF/HC meal. Healthcare providers should consider these formulations as tools to optimize treatment based on each patient's individual needs.

Indexed as

acneacne therapyformulationisotretinoin

Identifiers

PMID35291260
PMCPMC8903225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.